Related Experiment Videos
A phase I-II study of maytansine utilizing a weekly schedule
Cancer
|September 1, 1980
Summary
Maytansine, an antitumor antibiotic, showed dose-limiting neurologic toxicities in Phase I-II trials. Limited partial remissions were observed in heavily pretreated patients with lung cancer and melanoma.
Area of Science:
- Pharmacology
- Oncology
- Antitumor Antibiotics
Background:
- Maytansine is a novel ansa macrolide antitumor antibiotic.
- Antitumor agents are crucial in cancer treatment.
Purpose of the Study:
- To evaluate the safety and efficacy of Maytansine in cancer patients.
- To determine dose-limiting toxicities and observe antitumor responses.
Main Methods:
- A Phase I-II clinical study involving 107 patients.
- Dose escalation to identify toxic reactions and therapeutic effects.
- Biopsies to assess mitotic arrest patterns.
Main Results:
- Dose-limiting toxicities were neurologic (lethargy, paresthesias) at 0.75-1.0 mg/M2.
- Gastrointestinal and neurologic toxicities increased with dose.
- Three partial remissions observed in heavily pretreated patients (lung cancer, melanoma).
- Maytansine demonstrated peak mitotic arrest at 24 hours.
Conclusions:
- Maytansine exhibits dose-dependent toxicities, primarily neurologic.
- The drug showed limited efficacy in heavily pretreated patients.
- Further investigation into Maytansine's therapeutic potential is warranted.